Clinical Trial Update: Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating zanubrutinib with tislelizumab in B-cell malignancies has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Tislelizumab (tislelizumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Lymphoma, Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2022-07-01